Estimating the Global Prevalence of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2024 Jul 8

PMID 38974573

Authors

Yichao Wang

Jiaye Liu

Yiqiao Fang

Shengliang Zhou

Xueting Liu

Zhihui Li

Affiliations

Soon will be listed here.

Abstract

Background: Chronic kidney disease (CKD)-related secondary hyperparathyroidism (SHPT) is associated with higher morbidity and death. The goal of this study was to mine the SHPT data already available to do a meta-analysis on the global prevalence of SHPT caused by CKD.

Methods: Embase, Medline, Web of Science, Cochrane Central Databases, and Google Scholar were searched to identify studies on the prevalence of SHPT due to CKD from inception to November 2023. Pooled prevalence was calculated using the DerSimonian-Laird random effects model with a logit transformation.

Results: Twenty-one eligible studies involving 110977 patients were included. Our results revealed that the estimated global prevalence of SHPT due to CKD was 49.5% (95% CI 30.20-68.18), regardless of the diagnostic criteria. For subgroup analysis, Southern Asia (84.36%, 95% CI 79.35-88.34) had a significantly higher SHPT prevalence than other geographic regions. SHPT due to CKD was most prevalent in China (85.14%, 95% CI 81.74-88.00).

Conclusions: SHPT due to CKD is highly prevalent. This necessitates awareness and therapeutic approaches from primary care physicians, medical professionals, and health strategy authorities.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO, identifier CRD42024514007.

Citing Articles

Assessment of hyperparathyroidism secondary to CKD beyond laboratory tests: the important validation of the Parathyroid Assessment of Symptom (PAS) questionnaire for Portuguese language (Brazil).

Barreto F, Santos C J Bras Nefrol. 2024; 46(4):e2024E009.

PMID: 39585953 PMC: 11588316. DOI: 10.1590/2175-8239-JBN-2024-E009en.

References

Ghosh B, Brojen T, Banerjee S, Singh N, Singh S, Sharma O . The high prevalence of chronic kidney disease-mineral bone disorders: A hospital-based cross-sectional study. Indian J Nephrol. 2012; 22(4):285-91. PMC: 3495351. DOI: 10.4103/0971-4065.101249. View

Sutton W, Chen X, Patel P, Karzai S, Prescott J, Segev D . Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients. Surgery. 2021; 171(1):69-76. PMC: 8688275. DOI: 10.1016/j.surg.2021.03.067. View

Xu Y, Evans M, Soro M, Barany P, Carrero J . Secondary hyperparathyroidism and adverse health outcomes in adults with chronic kidney disease. Clin Kidney J. 2021; 14(10):2213-2220. PMC: 8483675. DOI: 10.1093/ckj/sfab006. View

Abdu A, Abdu A, Arogundade F . Prevalence and pattern of chronic kidney disease-mineral bone disorders among hemodialysis patients in kano, northwest nigeria. Ann Afr Med. 2019; 18(4):191-195. PMC: 6918790. DOI: 10.4103/aam.aam_18_19. View

Murton M, Goff-Leggett D, Bobrowska A, Garcia Sanchez J, James G, Wittbrodt E . Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review. Adv Ther. 2020; 38(1):180-200. PMC: 7854398. DOI: 10.1007/s12325-020-01568-8. View

Wang F, Yang C, Long J, Zhao X, Tang W, Zhang D . Executive summary for the 2015 Annual Data Report of the China Kidney Disease Network (CK-NET). Kidney Int. 2019; 95(3):501-505. DOI: 10.1016/j.kint.2018.11.011. View

Hedgeman E, Lipworth L, Lowe K, Saran R, Do T, Fryzek J . International burden of chronic kidney disease and secondary hyperparathyroidism: a systematic review of the literature and available data. Int J Nephrol. 2015; 2015:184321. PMC: 4396737. DOI: 10.1155/2015/184321. View

Jankowski J, Floege J, Fliser D, Bohm M, Marx N . Cardiovascular Disease in Chronic Kidney Disease: Pathophysiological Insights and Therapeutic Options. Circulation. 2021; 143(11):1157-1172. PMC: 7969169. DOI: 10.1161/CIRCULATIONAHA.120.050686. View

Capusa C, Chirculescu B, Vladu I, Viasu L, Lipan M, Mota E . THE PREVALENCE OF BIOCHEMICAL ABNORMALITIES OF CHRONIC KIDNEY DISEASE. MINERAL AND BONE DISORDERS IN UNTREATED NON-DIALYSIS PATIENTS - A MULTICENTER STUDY. Acta Endocrinol (Buchar). 2019; 12(3):282-290. PMC: 6535263. DOI: 10.4183/aeb.2016.282. View

10.

Jovanovich A, Chonchol M, Cheung A, Kaufman J, Greene T, Roberts W . Racial differences in markers of mineral metabolism in advanced chronic kidney disease. Clin J Am Soc Nephrol. 2012; 7(4):640-7. PMC: 3315341. DOI: 10.2215/CJN.07020711. View

11.

Liu J, Ma B, Cao W, Li M, Bramer W, Peppelenbosch M . Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. Transpl Infect Dis. 2019; 21(2):e13047. PMC: 6850617. DOI: 10.1111/tid.13047. View

12.

Oliveira R, Silva E, Charpinel D, Gueiros J, Neves C, Sampaio E . Secondary hyperparathyroidism status in Brazil: Brazilian census of parathyroidectomy. J Bras Nefrol. 2011; 33(4):457-62. View

13.

Rahimian M, Sami R, Behzad F . Evaluation of secondary hyperparathyroidism in patients undergoing hemodialysis. Saudi J Kidney Dis Transpl. 2007; 19(1):116-9. View

14.

Gimba Z, Abene E, Agbaji O, Agaba E . Secondary hyperparathyroidism among Nigerians with chronic kidney disease. Afr Health Sci. 2019; 18(2):446-457. PMC: 6306980. DOI: 10.4314/ahs.v18i2.30. View

15.

Salem M . Hyperparathyroidism in the hemodialysis population: a survey of 612 patients. Am J Kidney Dis. 1997; 29(6):862-5. DOI: 10.1016/s0272-6386(97)90459-5. View

16.

Kovesdy C, Ahmadzadeh S, Anderson J, Kalantar-Zadeh K . Secondary hyperparathyroidism is associated with higher mortality in men with moderate to severe chronic kidney disease. Kidney Int. 2008; 73(11):1296-302. DOI: 10.1038/ki.2008.64. View

17.

Vikrant S, Parashar A . Prevalence and severity of disordered mineral metabolism in patients with chronic kidney disease: A study from a tertiary care hospital in India. Indian J Endocrinol Metab. 2016; 20(4):460-7. PMC: 4911834. DOI: 10.4103/2230-8210.183457. View

18.

Okoye J, Arodiwe E, Ulasi I, Ijoma C, Onodugo O . Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria. Afr Health Sci. 2016; 15(3):941-8. PMC: 4765478. DOI: 10.4314/ahs.v15i3.31. View

19.

Gutierrez O, Isakova T, Andress D, Levin A, Wolf M . Prevalence and severity of disordered mineral metabolism in Blacks with chronic kidney disease. Kidney Int. 2008; 73(8):956-62. DOI: 10.1038/ki.2008.4. View

20.

Arevalo-Lorido J, Carretero-Gomez J, Garcia-Sanchez F, Macia-Botejara E, Ramiro-Lozano J, Masero-Carretero A . Secondary hyperparathyroidism prevalence and profile, between diabetic and non-diabetic patients with stage 3 to 4 chronic kidney disease attended in internal medicine wards. MiPTH study. Diabetes Metab Syndr. 2016; 10(2 Suppl 1):S16-21. DOI: 10.1016/j.dsx.2016.01.011. View